

Supplementary Table 1 Prespecified eligibility criteria

Participants	Interventions	Comparison	Outcomes	Study types
age >18years, spontaneous intracerebral hemorrhage	Intervention Laboratory indicating high NLR	group: Control laboratory value indicating NLR	group: Primary Hematoma Secondary Perihematoma edema growth. Only studies using one or more of these outcomes	Randomized control trial, observational cohort study

NLR: Neutrophil-to-lymphocyte ratio.

Supplementary Table 2 Newcastle Ottawa Scale for hematoma expansion

Ref.	Selection			Comparability			Outcome			Overall quality
	Representative cohort	Control selection	Ascertainment of exposure	Outcome of not present at start of study	Control for intracerebral hemorrhage severity	Control for systemic factors	Outcome assessment	Follow up length	Follow up availability	
Kim <i>et al</i> [31],	☆	☆	☆	☆	☆	-	☆	☆	☆	8/9 ☆

2023											
Chu <i>et al</i> [27],	☆	☆	☆	☆	☆	-	☆	☆	☆	8/9	☆
2023											
Alimohamma	☆	☆	☆	☆	☆	-	☆	☆	☆	8/9	☆
di <i>et al</i> [28],											
2022											
Zhang <i>et al</i> [32],	☆	☆	☆	☆	☆	-	☆	☆	☆	8/9	☆
2022											
Fonseca <i>et al</i> [25],	☆	☆	☆	☆	☆	☆	☆	☆	☆	9/9	☆
2019											
Pektezel <i>et al</i> [22],	☆	☆	☆	☆	☆	-	☆	☆	☆	8/9	☆
2019											
Wang <i>et al</i> [26],	☆	☆	☆	☆	☆	-	☆	☆	☆	8/9	☆
2019											
Zhang <i>et al</i> [23],	☆	☆	☆	☆	☆	-	☆	☆	☆	8/9	☆
2018											

Supplementary table 3 Newcastle Ottawa Scale for perihematoma edema growth

Ref.	Representative cohort	Selection			Comparability		Outcome				Overall quality
		Control selection	Ascertainment of exposure	Outcome of not present at start of study	Control for hemorrhage	intracerebral severity	Control for other factors	Outcome assessment	Follow up length	Follow up availability	
Mao <i>et al</i> [30], 2024	☆	☆	☆	☆	☆		-	☆	☆	☆	8/9 ☆
Pisco <i>et al</i> [29], 2023	☆	☆	☆	☆	☆		-	☆	☆	☆	8/9 ☆
Gusdon <i>et al</i> [24], 2017	☆	☆	☆	☆	☆		-	☆	☆	☆	8/9 ☆